The ALS Association

ALS Ice Bucket Challenge Progress

The ALS Association Hosts Public “Ask The Experts” Panel Discussion

Part of the MND/ALS International Alliance Meeting
Wednesday, December 9, 2015
2:00-4:00 pm ET
JW Marriott Grande Lakes, Orlando, FL

Lucie Bruijn, PhD, MBA, The ALS Association’s Chief Scientist will discuss some of the exciting new research projects supported by The ALS Association, including how collaboration with academia and industry partners have contributed to a better understanding of the disease, and facilitated preclinical trials and studies. Dr. Bruijn will facilitate a discussion with a panel of international researchers who will be offering insights into research involving genetics, biomarkers, drug development and clinical trials. This panel discussion is open to the public and will be presented Wednesday, December 9th from 2:00-4:00 pm ET at the JW Marriott Grande Lakes Hotel, in conjunction with the 23rd Annual Meeting of the International Alliance of ALS/MND Associations.

Dr. Bruijn’s presentation and the panel discussion will be live-streamed at for those unable to attend the research panel discussion in person.

Joining Dr. Bruijn for the panel discussion will be:

  • Richard Bedlack MD, PhD, MS. Dr. Bedlack is Associate Professor of Neurology and Director, Duke ALS Clinic. He also leads ALS Untangled, a network of physicians and researchers investigating alternative and off-label treatments for ALS. Dr. Bedlack’s recent research also resulted in the identification of a newly associated gene, which is thought to play a role in inflammation and damaged cell clearance associated with ALS.
  • Michael Benatar, MD, PhD. Dr. Benatar is Professor of Neurology and the Chief of the Neuromuscular Division in the Department of Neurology at the University of Miami. He is the first incumbent of the Walter Bradley Chair in ALS Research. With a focus on familial ALS and genetics, Dr. Benatar leads the CReATe Research Consortium which investigates the relationship between phenotype and genotype in ALS and the development of biomarkers that might be useful in therapy development.
  • Ammar Al-Chalabi, M.D. Professor of Neurology and Complex Disease Genetics, and Director of King’s MND Care and Research Centre at King’s College in London. Dr. Al-Chalabi’s research focuses on understanding what causes or modifies ALS as a way of finding new, effective treatments. His studies involve genes, lifestyle and the different clinical patterns of ALS. Dr. Al-Chalabi’s current research studies investigate the genetic susceptibility in ALS, and the relationship between cognitive changes and physical symptoms in ALS.
Powered by Blackbaud
nonprofit software